| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3504553 | The Lancet | 2005 | 7 Pages |
SummaryBackgroundStatin therapy reduces the rates of heart attack, stroke, and revascularisation among a wide range of individuals. Reliable assessment of its cost-effectiveness in different circumstances is needed.Methods20 536 adults (aged 40–80 years) with vascular disease or diabetes were randomly allocated 40 mg simvastatin daily (10 269) or placebo (10 267) for an average of 5 years. Comparisons were made of hospitalisation and statin costs (2001 UK prices) during the scheduled treatment period between all simvastatin-allocated versus all placebo-allocated participants. Cost-effectiveness was estimated among different categories of participant.FindingsAllocation to simvastatin was associated with a highly significant 22% (95% CI 16–27; p<0·0001) proportional reduction in hospitalisation costs for all vascular events, with similar proportional reductions in every subcategory of participant studied. During an average of 5 years, estimated absolute reductions in vascular event costs per person allocated 40 mg simvastatin daily ranged from UK£847 (SE 137) in the highest risk quintile studied to £264 (48) in the lowest. Mean excess cost of statin therapy among participants allocated simvastatin was £1497 (8), with similar absolute increases in every subcategory. Costs of preventing a major vascular event with 40 mg simvastatin daily ranged from £4500 (95% CI 2300–7400) among participants with a 42% 5-year major vascular event rate to £31 100 (22 900–42 500) among those with a 12% rate (corresponding to 5-year major coronary event rates of 22% and 4%, respectively).InterpretationStatin therapy is cost effective for a wider range of individuals with vascular disease or diabetes than previously recognised (particularly with lower-priced generics). It would be appropriate to consider reducing the estimated level of vascular event risk at which statin therapy is recommended.
